Dopamine dysregulation syndrome in non-Parkinson’s disease patients: a systematic review

2019 ◽  
Vol 27 (5) ◽  
pp. 456-461
Author(s):  
Jodi Cartoon ◽  
Jothi Ramalingam
Keyword(s):  
Systematic Review ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Replacement Therapy ◽  
Diagnostic Criteria ◽  
Case Reports ◽  
Factitious Disorder ◽  
Novelty Seeking ◽  
Dopamine Dysregulation Syndrome ◽  
Dopamine Replacement Therapy

Objectives: To explore the presence of dopamine dysregulation syndrome in non-Parkinson’s disease patients receiving dopamine replacement therapy. Methods: Electronic searches were conducted of Medline, Embase, PsycINFO and PreMedline to capture articles related to dopamine misuse or factitious disorder combined with the presence of dopamine replacement therapy or a non-Parkinson’s disease population. In total, 430 articles were reviewed and studies that addressed dopamine dysregulation syndrome in non-Parkinson’s disease patients were included. Results: Nine case reports were identified. Conclusions: The pathophysiology underlying dopamine dysregulation syndrome has been thoroughly explored with numerous mechanisms posited. What remains unclear is whether dopamine dysregulation syndrome is a phenomenon specific to Parkinson’s disease, as indicated in the proposed diagnostic criteria. A more useful predictor of susceptibility to dopamine dysregulation syndrome may be temperamental traits such as novelty seeking and impulsivity, which overlap with predisposing factors for an addiction disorder.

A systematic review on the applications of resting-state fMRI in Parkinson's disease: Does dopamine replacement therapy play a role?

Cortex ◽  
2015 ◽  
Vol 73 ◽  
pp. 80-105 ◽  
Author(s):  
Masoud Tahmasian ◽  
Lisa M. Bettray ◽  
Thilo van Eimeren ◽  
Alexander Drzezga ◽  
Lars Timmermann ◽  
...  
Keyword(s):  
Systematic Review ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Replacement Therapy ◽  
Resting State ◽  
Resting State Fmri ◽  
Dopamine Replacement Therapy

Hypomania and mania related to dopamine replacement therapy in Parkinson's disease

2014 ◽  
Vol 20 (4) ◽  
pp. 421-427 ◽  
Author(s):  
Franziska Maier ◽  
Josuah Merkl ◽  
Anna L. Ellereit ◽  
Catharine J. Lewis ◽  
Carsten Eggers ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Replacement Therapy ◽  
Dopamine Replacement Therapy

scholarly journals Parkinson’s Disease and Metal Storage Disorders: A Systematic Review

2018 ◽  
Vol 8 (11) ◽  
pp. 194 ◽  
Author(s):  
Edward Botsford ◽  
Jayan George ◽  
Ellen Buckley
Keyword(s):  
Systematic Review ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Wilson’S Disease ◽  
Case Reports ◽  
Hereditary Hemochromatosis ◽  
Wilson's Disease ◽  
Neurological Dysfunction ◽  
Cross Sectional ◽  
Storage Disorders

Metal storage disorders (MSDs) are a set of rare inherited conditions with variable clinical pictures including neurological dysfunction. The objective of this study was, through a systematic review, to identify the prevalence of Parkinsonism in patients with MSDs in order to uncover novel pathways implemented in Parkinson’s disease. Human studies describing patients of any age with an MSD diagnosis were analysed. Foreign language publications as well as animal and cellular studies were excluded. Searches were conducted through PubMed and Ovid between April and September 2018. A total of 53 publications were identified including 43 case reports, nine cross-sectional studies, and one cohort study. The publication year ranged from 1981 to 2018. The most frequently identified MSDs were Pantothenate kinase-associated neurodegeneration (PKAN) with 11 papers describing Parkinsonism, Hereditary hemochromatosis (HH) (7 papers), and Wilson’s disease (6 papers). The mean ages of onset of Parkinsonism for these MSDs were 33, 53, and 48 years old, respectively. The Parkinsonian features described in the PKAN and HH patients were invariably atypical while the majority (4/6) of the Wilson’s disease papers had a typical picture. This paper has highlighted a relationship between MSDs and Parkinsonism. However, due to the low-level evidence identified, further research is required to better define what the relationship is.

Impulse-Control Disorders in Parkinson's Disease

CNS Spectrums ◽  
2008 ◽  
Vol 13 (8) ◽  
pp. 690-698 ◽  
Author(s):  
Joseph M. Ferrara ◽  
Mark Stacy
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Replacement Therapy ◽  
Impulse Control ◽  
Neurodegenerative Disorder ◽  
Psychosocial Impairment ◽  
Olfactory Loss ◽  
Dopamine Replacement Therapy ◽  
Compulsive Behaviors ◽  
Non Motor Symptoms

ABSTRACTParkinson's disease is a neurodegenerative disorder characterized by bradykinesia, rigidity, postural instability, and resting tremor. Increasingly, Parkinson's disease has been associated with a broad spectrum of non-motor symptoms, such as olfactory loss, sleep disorders, autonomic dysfunction, cognitive impairment, psychosis, depression, anxiety, and apathy. In addition, a minority of Parkinson's disease patients develop compulsive behaviors while receiving dopamine-replacement therapy, including medication hoarding, pathological gambling, binge eating, hyperlibidinous behavior, compulsive shopping, and punding. These behaviors may result in psychosocial impairment for patients and therapeutic challenges for clinicians. This article reviews the anatomic substrates, behavioral spectrum, associated factors, and potential treatments for dopamine-replacement therapy-related compulsions in Parkinson's disease.

scholarly journals The Role of the Subthalamic Nucleus in Inhibitory Control of Oculomotor Behavior in Parkinson’s Disease

2019 ◽  
Author(s):  
Shahab Bakhtiari ◽  
Ayca Altinkaya ◽  
Christopher C. Pack ◽  
Abbas F. Sadikot
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Replacement Therapy ◽  
Subthalamic Nucleus ◽  
Error Rate ◽  
Oculomotor Behavior ◽  
Dopamine Replacement Therapy ◽  
Anti Saccades ◽  
Stn Dbs

AbstractThe ability to inhibit an inappropriate action in a context is an important part of the human cognitive repertoire, and deficiencies in this ability are common in neurological and psychiatric disorders. An anti-saccade is a simple experimental task within the oculomotor repertoire that can be used to test this ability. The task involves an inhibition of a saccade to the peripheral target (pro-saccade) and generation of a voluntary eye movement toward the mirror position (anti-saccade). Previous studies provide evidence for a possible contribution from the basal ganglia in anti-saccade behavior. However, the precise role of different components in generation of anti-saccade behavior is still uncertain. Parkinson’s disease patients with implanted deep brain stimulation (DBS) in subthalamic nucleus (STN) provide us with a unique opportunity to investigate the role of STN in anti-saccade behavior. Previous attempts to show the effect of STN DBS on anti-saccades have produced conflicting observations. For example, the effect of STN DBS on anti-saccade error rate is not yet clear. Part of this inconsistency may be related to differences in dopaminergic states in different studies. Here, we tested Parkinson’s disease patients on anti- and pro-saccade tasks ON and OFF STN DBS and ON and OFF dopaminergic medication. We made three main observations. First, STN DBS increases the anti-saccade error rate while patients are OFF dopamine replacement therapy. Second, there is an interaction between dopamine replacement therapy and STN DBS. More specifically, L-dopa reduces the effect of STN DBS on anti-saccade error rate. Third, STN DBS can induce different effects on pro- and anti-saccades in different patients. These observations provide evidence for an important role for the STN in the circuitry underlying context-dependent modulation of visuomotor action selection.

Sign in / Sign up

Export Citation Format

Share Document